Since CD133 is expressed in MLL-r B-ALL cells, preclinical studies have also proposed the application of CD19/CD133 bispecific CAR T-cells (29), with the findings showing the synergistic effect of CD19 and CD133 and that T-cells simultaneously targeting CD19 and CD133 possess greater recognition efficacy than single-targeted T-cells in vitro and mouse models. This evidence concerns the gene KMT2A and acute lymphoblastic leukemia.